Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Takeda Pharmaceutical shares in Ireland | $16.67

6 steps guide to buying and managing Takeda Pharmaceutical share in just a few minutes.

Posted

Fact checked
Picture not described

Takeda Pharmaceutical Company Limited is a drug manufacturers-specialty & generic business based in the US. Takeda Pharmaceutical shares (TAK) are listed on the NYSE and all prices are listed in US Dollars. Takeda Pharmaceutical employs 47,495 staff and has a market cap (total outstanding shares value) of USD$54.1 billion.

How to buy shares in Takeda Pharmaceutical from Ireland

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Takeda Pharmaceutical Find the stock by name or ticker symbol: TAK. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Takeda Pharmaceutical reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$16.67, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Takeda Pharmaceutical, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Takeda Pharmaceutical. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Compare online brokers to trade stocks, ETFs and CFDs

warning iconWarning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89 % of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Data indicated here is updated regularly
Name Product Number of Stocks CFDs Shares Available Markets Link
DEGIRO
Access to global markets
No
Yes
AU, AT, BE, CA, CH, CZ, DE, DK, ES, FR, FI, GR, HK, HU, IT, JP, NO, PT, PL, IE, SG, SE, TR, UK, US
Go to site
More Info
Your capital is at risk.
eToro
2,000+
Yes
Yes
Worldwide with exception.
Go to site
71% of CFD accounts lose money
More Info
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
Plus500
2,000+
Yes
Yes
US, UK, AU, DE, FR, IT, PT, GR, JP, SG, ZA, NL, FI, BE, DK, SE, CH, ES, AT, NO, HU, CZ, IE, PL, HK
Go to site
76.4% of CFD accounts lose money
More Info
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76.4% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
loading

Compare up to 4 providers

How has coronavirus impacted Takeda Pharmaceutical's share price?

Since the stock market crash in March caused by coronavirus, Takeda Pharmaceutical's share price has had significant negative movement.

Its last market close was USD$16.67, which is 11.28% down on its pre-crash value of USD$18.79 and 34.11% up on the lowest point reached during the March crash when the shares fell as low as USD$12.43.

If you had bought USD$1,000 worth of Takeda Pharmaceutical shares at the start of February 2020, those shares would have been worth USD$689.01 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$861.01.

Takeda Pharmaceutical share price

Use our graph to track the performance of TAK stocks over time.

Takeda Pharmaceutical shares at a glance

Information last updated 2021-01-21.
Latest market closeUSD$16.67
52-week rangeUSD$12.43 - USD$20.42
50-day moving average USD$18.3176
200-day moving average USD$17.8818
Wall St. target priceUSD$23.59
PE ratio 21.6636
Dividend yield USD$0.85 (4.83%)
Earnings per share (TTM) USD$0.8115

Is it a good time to buy Takeda Pharmaceutical stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Takeda Pharmaceutical price performance over time

Historical closes compared with the last close of $16.67

1 week (2021-01-15) -4.42%
1 month (2020-12-23) -8.81%
3 months (2020-10-23) 0.06%
6 months (2020-07-23) -3.92%
1 year (2020-01-23) -16.73%
2 years (2019-01-23) -16.44%
3 years (2018-01-23) -44.58%
5 years (2016-01-22) -29.78%

Is Takeda Pharmaceutical under- or over-valued?

Valuing Takeda Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Takeda Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Takeda Pharmaceutical's P/E ratio

Takeda Pharmaceutical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 22x. In other words, Takeda Pharmaceutical shares trade at around 22x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Takeda Pharmaceutical's PEG ratio

Takeda Pharmaceutical's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.1176. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Takeda Pharmaceutical's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Takeda Pharmaceutical financials

Gross profit TTM USD$2,201.5 billion
Return on assets TTM 1.2%
Return on equity TTM 1.18%
Profit margin 1.74%
Book value $12.5505
Market capitalisation USD$54.1 billion

TTM: trailing 12 months

Shorting Takeda Pharmaceutical shares

There are currently 7.6 million Takeda Pharmaceutical shares held short by investors – that's known as Takeda Pharmaceutical's "short interest". This figure is 15.5% up from 6.6 million last month.

There are a few different ways that this level of interest in shorting Takeda Pharmaceutical shares can be evaluated.

Takeda Pharmaceutical's "short interest ratio" (SIR)

Takeda Pharmaceutical's "short interest ratio" (SIR) is the quantity of Takeda Pharmaceutical shares currently shorted divided by the average quantity of Takeda Pharmaceutical shares traded daily (recently around 1.9 million). Takeda Pharmaceutical's SIR currently stands at 4.07. In other words for every 100,000 Takeda Pharmaceutical shares traded daily on the market, roughly 4070 shares are currently held short.

However Takeda Pharmaceutical's short interest can also be evaluated against the total number of Takeda Pharmaceutical shares, or, against the total number of tradable Takeda Pharmaceutical shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Takeda Pharmaceutical's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Takeda Pharmaceutical shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Takeda Pharmaceutical shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Takeda Pharmaceutical.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy Policy and Terms.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site